Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Colon cancer; rectal cancer Clinical Trials

A listing of Colon cancer; rectal cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (51) clinical trials

CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers

This is a phase 1/1b open label, multicenter, dose-selection study of CPI-006, a Type 2 humanized IgG1 antibody inhibiting enzymatic activity of CD73 and adenosine production. This trial will study the safety, tolerability, and anti-tumor activity of CPI-006 as a single agent, in combination with CPI-444, a small molecule targeting ...

Phase

A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies

RGX-202-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of ...

Phase

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies. In this dose escalation study, participants will receive AB154 administered intravenously as monotherapy or in combination ...

Phase

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

This is a phase 1 trial to evaluate the safety, the RP2D, and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative therapy for their type of solid cancer (eg, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, melanoma) and would ...

Phase

Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies after failing the current standard of care chemotherapy options for patients with advanced gastric cancer and other GI malignancies is an area or ...

Phase

A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

This is a two-part study of NUC-3373 administered every 2 weeks as an intravenous infusion, in separate combinations with leucovorin, oxaliplatin, oxaliplatin + bevacizumab, oxaliplatin + panitumumab, irinotecan, and irinotecan + cetuximab. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.

Phase

QUILT-3.017: Study of NEO-201 in Solid Tumors

The experimental drug called NEO-201 (the "study drug") is a monoclonal antibody that is being tested and is not approved for use in the United States by the FDA. The primary purpose of this first in human targeted phase 1 open-label study with NEO-201 in subjects with advanced solid tumors ...

Phase

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) ...

Phase

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies

Dose escalation of AB928 in combination with mFOLFOX at standard doses will be assessed in participants with advanced metastatic GEC or CRC. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of mFOLFOX. Dose expansion of AB928 in combination with mFOLFOX ...

Phase

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

This open-label Phase I study aims at assessing the safety, cell kinetics and clinical activity of the CYAD-101 treatment administered 3 times with a 2-week interval between each administration in metastatic CRC, concurrently with a standard chemotherapy treatment. The standard chemotherapy treatment consists of 6 consecutive cycles of FOLFOX administered ...

Phase